Trial Profile

An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APZ 2 (Primary)
Indications Epidermolysis bullosa
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors RHEACELL

Most Recent Events

06 Oct 2022 Status changed from active, no longer recruiting to completed.
09 Jun 2022 This trial has been completed in France, according to European Clinical Trials Database record.
31 Mar 2020 This trial has been suspended in Austria as per European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com